Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study

Kohei Ogawa; Kei Tamura; Katsunori Sakamoto; Naotake Funamizu; Masahiko Honjo; Mikiya Shine; Yusuke Nishi; Tomoyuki Nagaoka; Chihiro Ito; Miku Iwata; Mio Uraoka; Yasutsugu Takada

doi:10.12659/AOT.941346

12 September 2023: Original Paper

Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study

Kohei Ogawa ^ABCDEF* , Kei Tamura ^AB , Katsunori Sakamoto ^C , Naotake Funamizu ^B , Masahiko Honjo ^B , Mikiya Shine ^B , Yusuke Nishi ^B , Tomoyuki Nagaoka ^B , Chihiro Ito ^B , Miku Iwata ^B , Mio Uraoka ^B , Yasutsugu Takada ^AD

DOI: 10.12659/AOT.941346

Ann Transplant 2023; 28:e941346

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 2 Graft survival in donor-specific anti-human leukocyte antigen antibody (DSA)-positive, cross-reactive epitope group antibody (CREG)-alone-positive, and double-negative liver transplant recipients (IBM, SPSS statistics, ver. 28.0.1.0). The 1-year graft survival rate is 100% in both DSA-positive and CREG-alone-positive cases, and 87.5% in double-negative cases (p=0.289). DSA, donor-specific anti-human leukocyte antigen antibody; CREG, cross-reactive epitope group; LTx, liver transplantation.

Back to the Article

Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study

Your Privacy